Biologics Tied to Lower Eye Risk in Psoriasis - Poll - MDSpire

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

  • By

  • Andrea Surnit

  • April 20, 2026

  • 2 min

Share

Original Source(s)

Biologics Tied to Lower Eye Risk in Psoriasis

  • by Andrea Surnit

  • April 20, 2026

Related Content

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.